RxDoctor Payments Data

Christopher Olenek, DO

Family Medicine · Vero Beach, FLNPI 1932186558

Payments from drug & device makers

$1,346in general payments, 2019–2025

Across 38 payments — averaging $35.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$821
  • Lilly USA, LLC$179
  • Pfizer$70
  • Novo Nordisk$55
  • Mylan Specialty L.p.$35
  • AbbVie$29
  • plus $156 from 9 others

What the payments were for

  • Food & beverage$1,346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,346 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$115,553
Medicare patients
364
Services billed
1,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$61,028
MounjaroTirzepatide29$38,182
OzempicSemaglutide36$36,447
LinzessLinaclotide15$16,132
TrulicityDulaglutide12$12,253
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,868
Montelukast Sodium173$2,367
SynthroidLevothyroxine Sodium23$2,059
Tamsulosin Hcl97$1,879
Levothyroxine Sodium144$1,550
Clobetasol Propionate29$1,385
Atorvastatin Calcium97$1,271
Metoprolol Succinate79$1,190
Temazepam40$1,124
Rosuvastatin Calcium55$1,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$61,02854 claims
Lilly USA, LLCMounjaro, Trulicity$179$50,43541 claims
Novo NordiskOzempic$55$36,44736 claims
AbbVieLinzess, Synthroid$29$18,19138 claims
GSKTrelegy Ellipta$821$10,86815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →